How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment
A couple years back, some cardiovascular specialists at Boston’s Brigham and Women’s Hospital stumbled across a surprising result.
Novartis had tasked them with carrying out the long-range Phase III trial for canakinumab, an experimental anti-inflammatory drug the company was trying to market for cardiovascular disease. The main results were mixed — modest reductions in fatal cardiovascular events, clear side effects — but an additional, exploratory analysis, turned heads over in oncology: Across 10,061 patients, those who had received canakinumab were less likely to develop lung cancer; 33% less likely for the highest dosage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.